Monday, November 27, 2017

Odonate Therapeutics Seeks $182.5M In IPO

San Diego-based Odonate Therapeutics, a startup that says it is hoping to develop chemotherapy drugs, is looking to raised $182.5M in an IPO on the NASDAQ Global Select Market. The company has set its estimated IPO price range at between $24.00 and $27.00 per share. The company, which is backed by Tang Capital partners, Boxer Capital, Janus Capital Management, Sabby Management, Franklin Advisors, Solus, Arcus Venture Funds, Rock Springs Capital, and Samsara BioCapital, said it has applied to list as ODT. The company's IPO is being underwritten by Goldman Sachs & Co., Jeffries, and Cowen.